Subacute thyroiditis after COVID-19 vaccination: A systematic review of the literature DOI
Mohd Ashraf Ganie, Haroon Rashid, Ajaz Qadir

et al.

Thyroid Research and Practice, Journal Year: 2022, Volume and Issue: 19(1), P. 24 - 41

Published: Jan. 1, 2022

ABSTRACT Subacute thyroiditis (SAT) is a relatively mild and self-limiting thyroid disease caused by viral or postviral inflammatory process. Besides infection, severe acute respiratory syndrome coronavirus 2 vaccines may have role in SAT pathogenesis; however, the exact mechanism remains unknown. A systematic review was conducted to look into published cases of postvaccination SAT, evaluate their clinical characteristics, symptom resolution rate, determine differences clinicodemographic characteristics according vaccine type. PubMed, WHO COVID-19, The Cochrane Library, Science Direct, Embase, Scopus were searched until April 11, 2022. Original articles any design reporting due COVID-19 vaccination included. quality assessment performed using Joanna Briggs Institute’s Critical Appraisal Checklist for studies. Thirty-five including 86 retrieved included analysis. Of patients, 68 (79.1%) female. median age patients at time onset 41 (interquartile range [IQR] 35–50) years, they developed after 10 (IQR 5–15) days’ postvaccination. incidence more Asian countries (60.4%), most these receiving non-mRNA (P = 0.019). In cases, T3 (73%), T4 (77%), markers (90%) high, while stimulating hormone [TSH] (86%) low. Median TSH, free T3, 0.018 0.01–0.085) mIU/L, 3.87 1.9–6.8) pg/mL, 2.44 1.58–3.5) ng/dL, respectively. C-reactive-protein 28.6 mg/L 6.3–79.5) erythrocyte sedimentation rate 60 mm/h 41.5–76.5) elevated. 70 therapy, 71.4% treated with nonsteroidal anti-inflammatory drugs, 44.3% steroids, 37.1% beta-blockers. overall 77.0% (95% confidence interval [CI]: 66%–85%), female subjects likely achieve (odds ratio 4.98; 95% CI: 1.48–16.8; P 0.010). Despite trends, against recommended since exceedingly uncommon and, because it self-limiting, often linked favorable evolution long-term outcomes.

Language: Английский

COVID-19 vaccination and thyroiditis DOI Open Access
Süleyman Nahit Şendur, Seda Hanife Oğuz, Uğur Ünlütürk

et al.

Best Practice & Research Clinical Endocrinology & Metabolism, Journal Year: 2023, Volume and Issue: 37(4), P. 101759 - 101759

Published: March 3, 2023

Language: Английский

Citations

18
The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine DOI Creative Commons

Mihaela Popescu,

Adina Ghemigian,

Corina Maria Vasile

et al.

Diagnostics, Journal Year: 2022, Volume and Issue: 12(4), P. 960 - 960

Published: April 12, 2022

This is a review of full-length articles strictly concerning subacute thyroiditis (SAT) in relation to the SARS-CoV-2 virus infection (SVI) and COVID-19 vaccine (COV) that were published between 1st March 2020 21st 2022 PubMed-indexed journals. A total 161 cases reported as follows: 81 SAT-SVI (2 retrospective studies, 5 case series, 29 reports), 80 respective SAT-COV (1 longitudinal study, 14 17 reports; also, 1 prospective study included 12 patients, with 6 patients each category). To our knowledge, this represents largest cohort until present time. was detected adults aged 18 85 years, mostly middle-aged females. SAT-COVID-19 timing classifies SAT viral (synchronous infection, which an original feature SATs usually follow infection) post-viral (during recovery period or after within 8 weeks, up maximum 24 weeks). The clinical spectrum has two patterns: either accompanying severe multi-organ spreading (most frequent lung involvement) asymptomatic being single manifestation first presentation. Either way, may remain unrecognized. Some data suggest more intense neck pain, fever, hypothyroidism at 3 months are identified when compared non-SAT-SVI, but other authors have similar presentations outcomes. Post-COVID-19 fatigue be due residual post-SAT hypothyroidism. practical importance derives from fact thyroid hormone anomalies aggravate general status infections (particular concerns tachycardia/arrhythmias, cardiac insufficiency, ischemic events). If misdiagnosed, results unnecessary treatment anti-thyroid drugs even antibiotics for fever unknown cause. Once recognized, does not seem require particular approach non-COVID-19 cases, including need glucocorticoid therapy rate permanent complete resolution inflammation expected, except persistent follows few hours average 2 weeks (no pattern related second dose). Pathogenesis includes molecular mimicry immunoinflammatory anomalies, some suggested part ASIA syndrome (autoimmune/inflammatory induced by adjuvants). An alternative hypothesis vaccine-related increased autoimmunity vaccine-induced hyperviscosity; however, supported incomplete evidence. From what we know so far risk factors, prior episode non-SVI-SAT associated higher SAT-COV, nor previous history coronavirus itself. Post-vaccine less presentation good outcome. Generally, female sex prone developing any type SAT. HLA susceptibility probably both new types SATs. current low level statistical evidence expected change future. Practitioners should aware restrict immunization protocols case.

Language: Английский

Citations

28
Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study DOI Open Access
Adnan Batman, Dilek Yazıcı, Oğuz Dikbaş

et al.

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2023, Volume and Issue: 108(10), P. e1013 - e1026

Published: April 25, 2023

Abstract Context The aims of the study are to compare characteristics subacute thyroiditis (SAT) related different etiologies, and identify predictors recurrence SAT incident hypothyroidism. Methods This nationwide, multicenter, retrospective cohort included 53 endocrinology centers in Turkey. participants were divided into either COVID-19–related (Cov-SAT), SARS-CoV-2 vaccine–related (Vac-SAT), or control (Cont-SAT) groups. Results Of 811 patients, 258 (31.8%) Vac-SAT group, 98 (12.1%) Cov-SAT 455 (56.1%) Cont-SAT group. No difference was found between groups with regard laboratory imaging findings. etiology not an independent predictor In entire cohort, steroid therapy requirement younger age statistically significant for recurrence. C-reactive protein measured during onset, female sex, absence antithyroid peroxidase (TPO) positivity, (early) hypothyroidism, irrespective etiology. On other hand, probable established hypothyroidism differed from that Conclusion Since there is no terms follow-up parameters outcomes, COVID-19– can be treated followed up like classic SATs. Recurrence determined by requirement. Steroid independently predicts may sometimes transient overall also associated a lower risk

Language: Английский

Citations

13
Menstrual disturbances following COVID-19 vaccination: A probable puzzle about the role of endocrine and immune pathways DOI Open Access
Farima Rahimi Mansour, Amirreza Keyvanfar, Hanieh Najafiarab

et al.

Journal of Reproductive Immunology, Journal Year: 2023, Volume and Issue: 158, P. 103952 - 103952

Published: May 12, 2023

Language: Английский

Citations

13
Differences in Clinical Aspects Between Subacute Thyroiditis Associated with COVID-19 Vaccines and Classical Subacute Thyroiditis DOI Open Access
Ömercan Topaloğlu, Sakin Tekin,

Seda Nur Topaloğlu

et al.

Hormone and Metabolic Research, Journal Year: 2022, Volume and Issue: 54(06), P. 380 - 388

Published: May 1, 2022

Abstract Subacute thyroiditis (SAT) developed after SARS-CoV-2 vaccines has been less studied. We aimed to compare classical SAT and in the context of clinical aspects. Adults with detected 90 days COVID-19 vaccination (CoronaVac or Pfizer/BioNTech) were grouped as Vac-SAT. Those a history upper respiratory tract infection 6 months before vaccination, another antiviral vaccine excluded. pandemic Classical-SAT. Of total (n=85), female/male (54/31) ratio age [43 (23–65)] similar Vac-SAT (n=23) Classical-SAT (n=62). Duration between was 45 (7–90) days, CoronaVac-SAT (n=5) BioNTech-SAT (n=18). SAT-duration 28 (10–150) higher than (p=0.023). 1st dose minority (n=2) (n=3) (p=0.263). Previous LT4 use, TSH elevation resolution more frequent (p=0.027 p=0.041). included considerable number patients occurred vaccines. cannot provide clear evidence regarding association SAT. associated CoronaVac BioNTech seems unlikely be dose, have longer duration, likely previous use lead should followed-up vaccination.

Language: Английский

Citations

10
SARS-CoV-2-Vaccine-Related Endocrine Disorders: An Updated Narrative Review DOI Creative Commons
Avraham Ishay, Kira Oleinikov, Elena Chertok Shacham

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(7), P. 750 - 750

Published: July 8, 2024

The emergence of the COVID-19 pandemic has led to rapid and worldwide development investigation multiple vaccines. While most side effects these vaccines are mild transient, potentially severe adverse events may occur involve endocrine system. This narrative review aimed explore current knowledge on potential following vaccination, with thyroid disorders being common. Data about pituitary, adrenal, diabetes, gonadal also reviewed. provides a comprehensive understanding pathogenesis associated SARS-CoV-2 PubMed/MEDLINE, Embase database (Elsevier), Google Scholar searches were performed. Case reports, case series, original studies, reviews written in English published online up 31 August 2023 selected accumulating. However, their causal relationship is not strong enough make definite conclusion, further studies needed clarify mechanisms linked

Language: Английский

Citations

1
Subacute thyroiditis after COVID-19 vaccination: A systematic review of the literature DOI
Mohd Ashraf Ganie, Haroon Rashid, Ajaz Qadir

et al.

Thyroid Research and Practice, Journal Year: 2022, Volume and Issue: 19(1), P. 24 - 41

Published: Jan. 1, 2022

ABSTRACT Subacute thyroiditis (SAT) is a relatively mild and self-limiting thyroid disease caused by viral or postviral inflammatory process. Besides infection, severe acute respiratory syndrome coronavirus 2 vaccines may have role in SAT pathogenesis; however, the exact mechanism remains unknown. A systematic review was conducted to look into published cases of postvaccination SAT, evaluate their clinical characteristics, symptom resolution rate, determine differences clinicodemographic characteristics according vaccine type. PubMed, WHO COVID-19, The Cochrane Library, Science Direct, Embase, Scopus were searched until April 11, 2022. Original articles any design reporting due COVID-19 vaccination included. quality assessment performed using Joanna Briggs Institute’s Critical Appraisal Checklist for studies. Thirty-five including 86 retrieved included analysis. Of patients, 68 (79.1%) female. median age patients at time onset 41 (interquartile range [IQR] 35–50) years, they developed after 10 (IQR 5–15) days’ postvaccination. incidence more Asian countries (60.4%), most these receiving non-mRNA (P = 0.019). In cases, T3 (73%), T4 (77%), markers (90%) high, while stimulating hormone [TSH] (86%) low. Median TSH, free T3, 0.018 0.01–0.085) mIU/L, 3.87 1.9–6.8) pg/mL, 2.44 1.58–3.5) ng/dL, respectively. C-reactive-protein 28.6 mg/L 6.3–79.5) erythrocyte sedimentation rate 60 mm/h 41.5–76.5) elevated. 70 therapy, 71.4% treated with nonsteroidal anti-inflammatory drugs, 44.3% steroids, 37.1% beta-blockers. overall 77.0% (95% confidence interval [CI]: 66%–85%), female subjects likely achieve (odds ratio 4.98; 95% CI: 1.48–16.8; P 0.010). Despite trends, against recommended since exceedingly uncommon and, because it self-limiting, often linked favorable evolution long-term outcomes.

Language: Английский

Citations

1